No. | Author (yr.) | Age/Gender (Ethnicity) | Primary site | Immunophenotype | BCR/TCR | Treatment | Follow-up (months) |
---|---|---|---|---|---|---|---|
1 | Present study | 30/F (Chinese) | Breast,stomach | CD20+++, CD3 + , CD4 + , CD56+++, TIA-1+, EBER(+), Ki67(90%) | +/+ | CT (SMILE) | 11,Alive |
2 | Huang,et al. (2020) | 67/M (Chinese) | Testis | CD20 + , CD3 + , CD2 + , CD7 + , CD56 + , TIA-1+,Gran B+, Perforin+,EBER(+),Ki67(90%) | +/− | Or + CT (P-GEMOX) | 4, Alive |
3 | Huang,et al. (2020) | 41/F (Chinese) | Nasal cavity | CD20 + , CD3 + , CD56 + , TIA-1+,Gran B+, Perforin+, EBER(+),Ki67(70%) | NA/NA | CT (EPOCH) | NA |
4 | Huang,et al. (2020) | 37/F (Chinese) | Skin | CD20 + , CD3 + , CD2 + , CD56 + , TIA-1+,Gran B+, EBER(+), Ki67(60%) | −/− | CT (P-GEMOX) | 9,DOD |
5 | Huang,et al. (2020) | 62/M (Chinese) | Nasal cavity | CD20 + , CD3 + , CD2 + , CD7p + , CD56 + , TIA-1+,Gran B+, Perforin+,EBER(+),Ki67(60%) | NA/NA | CT (AspaMetDex + P-GEMOX) | 18,DOD |
6 | Huang,et al. (2020) | 79/M (Chinese) | Testis | CD20 + , CD3 + , CD2p + , TIA-1+, EBER(+), Ki67(80%) | −/− | Or | 0.5,DOD |
7 | Huang,et al. (2020) | 67/M (Chinese) | Nasal cavity | CD20 + , CD3 + , CD7 + , CD56 + , TIA-1+,Gran B+, EBER(+),Ki67(80%) | −/− | CT (P-GEMOX) | 4,Alive |
8 | Huang,et al. (2020) | 29/M (Chinese) | Skin,scrotum | CD20 + , CD3 + , CD2 + , CD56+ TIA-1+,Gran B+, Perforin+, EBER(+),Ki67(80%) | −/− | CT(P-GEMOX +GVD+ Pembrolizumab+PDL1+ Benzamine +Daratumumab +PD-1) | 39,Alive |
9 | Huang,et al. (2020) | 37/M (Chinese) | Testis | CD20 + , CD3 + , CD7 + , CD56 + , CD79a F+, TIA-1+, EBER(+),Ki67(75%) | NA/NA | Or + CT (Not specific) | NA |
10 | Huang,et al. (2020) | 60/M (Chinese) | Soft tissue, LN Nasal cavity, scrotum | CD20 + , CD3 + , CD2 + , CD7 + , CD56 + , TIA-1+,Gran B+, Perforin+,EBER(+),Ki67(60%) | −/− | CT (Not specific) | 2,Alive |
11 | Huang,et al. (2020) | 56/M (Chinese) | Skin | CD20 + , CD3 + , CD2 + , CD7 + , CD56 + , TIA-1+,Gran B+, Perforin+,EBER(+),Ki67(50%) | −/− | CT (GEMOX-L) | 2, Alive |
12 | Huang,et al. (2020) | 81/M (Chinese) | Nasal cavity, scrotum | CD20 + , CD3 + , CD7 + , CD56 + , TIA-1+, EBER(+), Ki67(90%) | NA/NA | CT (P-GEMOX) | 3, Alive |
13 | Li D,et al. (2017) | 27/M (Chinese) | Left cerebellum | CD20 + , CD3 + , CD2 + , Gran B+, EBER(+),Ki67(85%) | +/− | RT + steroid therapy | 3,DOD |
14 | Huang YH,et al. (2015) | 48/M (Taiwancsc) | Stomach | CD20 + , CD3+, CD56 + , TIA-1+,Gran B+, EBER(+), Ki67(90%) | NA/− | C T (V I P, S M I L E) | 8,DOD |
15 | Tsai YC,et al. (2015) | 32/M (Taiwancsc) | Leg, back, LN | CD20 + , CD3 + , CD2 F + , CD56 + , TIA-1+,EBER(+) | NA/NA | CT (DICE) | 6,Alive |
16 | Jiang QP,et al. (2012) | 78/F (Chinese) | Nasal cavity | CD20 + , CD3 + , CD2 + , CD56 + , TIA-1+,Gran B+, EBER(+), Ki67(60%) | −/− | Observation without treatment | 6,Alive |
17 | Gill HS,et al. (2010) | 25/M (Chinese) | Chest wall | CD20+, CD2 + , CD56 + , TIA-1+, EBER(+),Ki67(90%) | −/− | NA | NA |
18 | Kobold S,et al. (2009) | 69/M (Caucasian) | Stomach | CD20 + , CD3 + , CD2 + , CD56 + , TIA-1+,Gran B+, Perforin+, | −/− | CT (CHOP) | 1,DOD |
19 | Ando J,et al. (2008) | 71/M (Japanese) | Thenar | CD20 + , CD3 + , CD2 + , CD56 + , TIA-1+,Gran B+, EBER(+) | −/− | CT (CHOP, ESHAP, and L-asparaginase) | 6,DOD |